PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)GlobeNewsWire • 12/02/25
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs UpdateGlobeNewsWire • 11/13/25
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025GlobeNewsWire • 11/10/25
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial ResultsGlobeNewsWire • 11/06/25
New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/30/25
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck CancerGlobeNewsWire • 10/29/25
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the PopulationGlobeNewsWire • 09/18/25
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/02/25
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerGlobeNewsWire • 08/25/25
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs UpdateGlobeNewsWire • 08/13/25
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/06/25
PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 ResultsGlobeNewsWire • 07/10/25
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCCGlobeNewsWire • 06/09/25
PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 06/02/25
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 05/22/25
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company ShowcaseGlobeNewsWire • 05/20/25
PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate UpdateGlobeNewsWire • 05/14/25
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/09/25
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual MeetingGlobeNewsWire • 05/08/25